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Background-—With advances in peripheral artery disease (PAD) treatments such as endovascular treatment (EVT), personalized
patient assessment is important. Data on sex differences in clinical outcome for PAD patients undergoing EVT have been limited,
and studies have produced conﬂicting results. This study sought to compare midterm clinical outcomes between women and men
in a large population of patients with PAD undergoing EVT.
Methods and Results-—The K-VIS ELLA (Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Disease)
registry is a nationwide, multicenter, observational study that includes 3073 PAD patients undergoing EVT. The study population
was divided into men (n=2523) and women (n=550). The primary outcome was a composite of death, myocardial infarction, and
major amputation; the secondary outcome included major adverse limb events. Women had more comorbidities and more severe
and complex target lesions than men. Women showed higher rates of death, myocardial infarction, or major amputation than men
(14.8% versus 9.8%, adjusted hazard ratio 1.350, 95% CI 1.017-1.792, P=0.038), and higher rates of major adverse limb events
(19.9% versus 14.5%, adjusted hazard ratio 1.301, 95% CI 1.014-1.670, P=0.039) and procedural complications (10.2% versus
5.9%, P<0.001) based on multivariable analysis. In patients with claudication, the primary outcome incidence was signiﬁcantly
higher in women (hazard ratio 2.088, 95% CI 1.421-3.068, P<0.001). In contrast, there was no signiﬁcant difference in primary
outcome for patients with critical limb ischemia between the 2 groups (hazard ratio 1.164, 95% CI 0.800-1.694, P=0.426). A
signiﬁcant interaction (P=0.035) between patient presentation and outcome was observed.
Conclusions-—In a large population of patients with PAD undergoing EVT, women had higher rates of death, myocardial infarction,
or major amputation than men and higher rates of complex lesions, procedural complications, and limb-speciﬁc adverse events.
( J Am Heart Assoc. 2019;8:e010849. DOI: 10.1161/JAHA.118.010849)
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C ardiovascular disease is the leading cause of death world-wide, and there has been a rapid increase in the past decade
in the prevalence of peripheral artery disease (PAD).1 For the
treatment of symptomatic PAD, endovascular treatment (EVT) has
evolvedwith thedevelopmentofnewdevicesand techniquesand is
now recommended as the reasonable revascularization option in
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various clinical and anatomical situations by current guidelines.2-4
There are well-established differences in the patterns of presen-
tation, lesion characteristics, clinical outcomes, and response to
therapy between male and female cardiovascular disease
patients.5-7 In particular, previous studies have demonstrated that
women with coronary artery disease who undergo percutaneous
coronary intervention are associated with higher rates of proce-
dural complications and poorer outcomes than men.8-11 These
differences may be related to an older age of presentation, smaller
vessel size, poorer overall health status, or a more severe
anatomical disease burden at presentation in female patients.
Similarly, several studieshaveevaluated thesex-relateddifferences
ofoutcomes inpatientswithPAD.12-17However, thesestudieshave
shown conﬂicting results with limited data on follow-up outcomes.
Therefore, we sought to evaluate sex-related differences in
presentation, disease severity, and procedural and midterm
follow-up outcomes in PAD patients treated with EVT using a
large-population, nationwide, multicenter, real-world registry.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Population and Data Collection
The K-VIS ELLA (Korean Vascular Intervention Society
Endovascular Therapy in Lower Limb Artery Diseases)
registry is a nationwide, multicenter, observational study
(ClinicalTrials.gov NCT02748226). Between January 2006
and July 2015, a total of 3434 PAD patients (5097 target
limbs) who were 20 years of age or older and treated with
EVT in 31 hospitals in Korea were enrolled. The K-VIS ELLA
registry study design and results have been described in
detail previously.18 A total of 3073 patients with 3972 target
limbs were ﬁnally included in the current analysis after
exclusion of 56 limbs with acute limb ischemia, 82 limbs
with Buerger disease, 11 limbs lacking procedural or in-
hospital data, 528 limbs lacking follow-up data after hospital
discharge, and 448 limbs treated for repeat revascularization
following the index procedure (Figure 1). Data on patient
demographics, baseline clinical and lesion characteristics,
medication history, clinical presentation, laboratory test
results, treatments, and follow-up outcomes were collected
from electronic medical records. Treatment strategy and
medication were selected at the operator’s discretion. The
study protocol was approved by the institutional review
board of each hospital and was conducted according to the
principles of the Declaration of Helsinki. The institutional
review boards of the participating hospitals waived the
requirement of informed consent due to the retrospective
nature of the study.
Deﬁnitions and Outcomes
PAD was deﬁned as ≥50% luminal narrowing of a lower-
extremity artery. Symptomatic lower-extremity ischemia was
stratiﬁed into 6 categories according to the Rutherford
classiﬁcation.19 Claudication was deﬁned as Rutherford
category 1, 2, or 3 diseases (mild, moderate, or severe
claudication, respectively). Critical limb ischemia (CLI) was
deﬁned as Rutherford category 4, 5, or 6 diseases (ischemic
resting pain, minor tissue loss, or major tissue loss,
respectively). Target lesions were classiﬁed using the
Trans-Atlantic Inter-Society Consensus for the Management
of Peripheral Arterial Disease.4 Multilevel disease was
deﬁned as the presence of signiﬁcant obstructive lesions
at more than 1 level in the same limb (aortoiliac,
femoropopliteal, and infrapopliteal arteries). Technical suc-
cess was deﬁned as evidence of successful revascularization
with residual stenosis lower than 30% after angioplasty and
absence of ﬂow-limiting dissection or a hemodynamically
signiﬁcant translesion pressure gradient. A major amputation
was deﬁned as any lower extremity amputation through or
proximal to the ankle joint; a minor amputation was deﬁned
as any lower extremity amputation distal to the ankle joint,
including the foot or toe(s).
The primary outcome for the present study was a
composite of all-cause mortality, myocardial infarction (MI),
and major amputation. Secondary outcomes included major
adverse limb events, deﬁned as a composite of major
amputation, minor amputation, and reintervention.
Clinical Perspective
What Is New?
• Among patients with peripheral artery disease undergoing
endovascular therapy, women were on average older, with
more complex lesion characteristics, higher rates of
comorbidity, and higher rates of procedural complications
than men.
• The cumulative incidences of 2-year cardiovascular and
limb-speciﬁc adverse events were higher in women than in
men, even after adjusting for baseline differences.
• These outcome differences were prominent in patients with
claudication, but not in those with critical limb ischemia.
What Are the Clinical Implications?
• Physicians should be aware that procedural complications
and prognosis may be worse among women with peripheral
artery disease undergoing endovascular therapy than among
men, particularly among those who present with claudication.
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Statistical Analyses
Continuous variables were compared using the Welch t test;
categorical data were compared using the chi-squared test.
Data were analyzed on a per-patient basis for clinical
characteristics and on a per-lesion basis for the limb, lesion,
or procedural characteristics. For per-limb or per-lesion
comparison of characteristics, a generalized estimating
equation was used to adjust intrasubject variability between
limbs from the same patient. Cumulative incidences of clinical
events were presented as Kaplan-Meier estimates and were
compared using a log-rank test. Hazard ratio (HR) and 95% CIs
were calculated using the Cox proportional hazards model to
compare the risk of adverse events between male and female
groups. In multivariable models, covariates suggested to be
relevant with a P<0.2 in univariate analysis, or that were
clinically relevant, were initially considered as candidate-
independent predictors of clinical events. Adjusted HRs and
95% CIs for clinical outcomes according to sex were obtained
using a ﬁnal Cox regression that included age, hypertension,
diabetes mellitus, chronic kidney disease, current smoking
status, previous history of amputation, EVT, MI, stroke, bypass
surgery, critical limb ischemia, multilevel disease, at least 1
Trans-Atlantic Inter-Society Consensus for the Management
of Peripheral Arterial Disease C or D, and body mass index
>30 kg/m2. All tests were 2-sided, and P<0.05 was
considered statistically signiﬁcant. Statistical analyses were
performed using the R Statistical Software (version 3.4.0; R
Foundation for Statistical Computing, Vienna, Austria).
Results
Clinical and Lesion Characteristics
Women comprised 18% of the study population. The mean age
of the study population was 68.39.4 years. Baseline clinical
characteristics and prescribed medications according to sex
are described in Table 1. Female patients were older, with a
higher body mass index, and had higher incidences of
hypertension, diabetes mellitus, chronic kidney disease, and
previous history of amputation and a lower incidence of
current smoking. Men were more likely to have intermittent
claudication symptoms, whereas women were more likely to
present with CLI as an indication for EVT. Medications at
discharge did not differ between the groups.
Sex-related differences in baseline lesion characteristics are
described in Table 2. Women showed more target lesions with
small vessels and were more likely to have multilevel diseases
than men. Women also showed target lesions with greater
percentage diameter stenosis, greater length, and a higher
proportion of Trans-Atlantic Inter-Society Consensus for the
Figure 1. Study ﬂow. EVT indicates endovascular treatment; K-VIS ELLA, Korean Vascular Intervention
Society Endovascular Therapy in Lower Limb Artery Disease; PAD, peripheral artery disease.
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Management of Peripheral Arterial Disease C or D classiﬁca-
tions. Pre- and postintervention ankle brachial indexes were
signiﬁcantly lower in women than in men (pre-EVT ankle
brachial index, 0.62 versus 0.66, P=0.013; post-EVT ankle
brachial index, 0.83 versus 0.88, P=0.002, respectively).
Procedural Characteristics and Complications
Baseline procedural characteristics according to sex are
shown in Table 2. Treatment strategies differed slightly
between the female and male groups, with more women
undergoing EVT with a balloon only and more men undergoing
EVT with self-expandable stents. Furthermore, the average
diameter of balloon or stent used was smaller in women than
Table 1. Baseline Clinical Characteristics
Women
(n=550) Men (n=2523) P Value
Demographics
Age, y 70.010.5 68.09.2 <0.001
Body mass index, kg/m2 24.64.8 23.33.2 <0.001
Cardiovascular risk factors
Current smoker 50 (9.1) 902 (35.8) <0.001
Hypertension 432 (78.5) 1825 (72.3) 0.003
Diabetes mellitus 353 (64.2) 1430 (56.7) 0.001
Dyslipidemia 227 (41.3) 968 (38.4) 0.223
Chronic kidney disease 140 (25.5) 466 (18.5) <0.001
Congestive heart failure 34 (6.2) 150 (5.9) 0.910
Previous history of MI 62 (11.3) 265 (10.5) 0.650
Previous history of stroke 81 (14.7) 373 (14.8) >0.999
Previous history of
bypass surgery
9 (1.6) 81 (3.2) 0.065
Previous history of
amputation
52 (9.5) 142 (5.6) 0.001
Previous history of EVT 49 (8.9) 250 (9.9) 0.524
Presentation of PAD
Rutherford classification <0.001
1 47 (8.5) 300 (11.9)
2 136 (24.7) 723 (28.7)
3 123 (22.4) 708 (28.1)
4 52 (9.5) 178 (7.1)
5 118 (21.5) 389 (15.4)
6 74 (13.5) 225 (8.9)
Critical limb ischemia 244 (44.4) 792 (31.4) <0.001
Medications at discharge
Aspirin 471 (85.6) 2121 (84.1) 0.567
Clopidogrel 448 (81.5) 2074 (82.2) 0.917
Cilostazol 185 (33.6) 900 (35.7) 0.663
Warfarin 40 (7.3) 180 (7.1) 0.982
Renin-angiotensin
receptor blocker
248 (45.1) 1118 (44.3) 0.928
b-blocker 205 (37.3) 846 (33.5) 0.231
Statin 381 (69.3) 1746 (69.2) 0.987
Calcium channel blocker 195 (35.5) 843 (33.4) 0.635
Diuretics 114 (20.7) 464 (18.4) 0.433
Data are presented as meanstandard deviation or n (%). EVT indicates endovascular
treatment; MI, myocardial infarction; PAD, peripheral artery disease.
Table 2. Baseline Lesion and Procedural Characteristics
Women
(n=550) Men (n=2523) P Value
Lesion characteristics
Number of target limbs N=704 N=3268
Involved vessel
Aortoiliac 264 (37.5) 1688 (51.7) <0.001
Femoral-popliteal 452 (64.2) 1787 (54.7) <0.001
Infrapopliteal 318 (45.2) 1149 (35.2) <0.001
Multilevel disease 294 (41.8) 1191 (36.4) 0.014
Pre-EVT ABI* 0.620.25 0.660.25 0.013
Post-EVT ABI† 0.830.22 0.880.21 0.002
In-stent restenosis 14 (2.0) 95 (2.9) 0.134
Total occlusion 388 (55.1) 1686 (51.6) 0.115
At least 1 TASC C or D 518 (73.6) 2202 (67.4) 0.002
Number of target lesions
per limb
1.60.8 1.50.8 0.006
Diameter stenosis, % 90.411.3 89.312.0 0.036
Lesion length, mm 131.899.0 118.197.6 0.006
Procedural characteristics
Total procedure number N=1120 N=4856
Successful EVT 637 (90.5) 2991 (91.5) 0.414
Treatment strategy <0.001
Balloon only 620 (55.4) 2157 (44.4)
Self-expandable stent 392 (35.0) 2166 (44.6)
Balloon-expandable stent 67 (6.0) 421 (8.7)
Others 41 (3.7) 112 (2.3)
Balloon diameter, mm 4.51.7 5.11.9 <0.001
Balloon length, mm 88.961.9 77.056.7 <0.001
Stent diameter, mm 7.11.8 7.71.8 <0.001
Stent length, mm 77.334.2 74.733.4 0.182
Contrast volume, mL 171.994.1 176.9102.0 0.297
Data are presented as meanstandard deviation or n (%). ABI indicates ankle-brachial
index; EVT, endovascular treatment; TASC, Trans-Atlantic Inter-Society Consensus.
*Pre-EVT ABI was available in 2428 limbs (61.1%).
†Post-EVT ABI was available in 1635 limbs (41.2%).
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in men. However, use of contrast volume did not differ
between the groups.
Total in-hospital procedural complications were more
frequently observed in women than in men (10.2% versus
5.9%, P<0.001) (Figure 2). In particular, bleeding complica-
tions, access site complications, and vascular rupture
occurred more commonly in women. However, in-hospital
mortality, unexpected amputation or reintervention rates, and
technical success rates were similar between these groups.
Follow-Up Clinical Outcomes
The median follow-up duration was 701 days (interquartile
range 299-995 days). Compared with the male group, the
women showed a signiﬁcantly higher rates of all-cause death,
MI, or major amputation (women versus men, 14.8% versus
9.8%, HR 1.706, 95% CI 1.345-2.163, P<0.001) (Table 3,
Figure 3A). The rates of major adverse limb events was also
signiﬁcantly higher in women (19.9% versus 14.5%, HR 1.506,
95% CI 1.191-1.905, P<0.001) (Table 3, Figure 3B). After
adjustment for baseline differences, sex-related differences
showed similar trends in a composite of all-cause death, MI,
or major amputation (14.8% versus 9.8%, adjusted HR 1.350,
95% CI 1.017-1.792, P=0.038) and in major adverse limb
events (19.9% versus 14.5%, adjusted HR 1.301, 95% CI
1.014-1.670, P=0.039).
Independent Predictors of Primary Outcomes and
Limb-Speciﬁc Adverse Events
On multivariable Cox regression model, female, CLI, chronic
kidney disease, previous history of amputation, stroke, bypass
surgery, and age were independent predictors of a composite
of all-cause death, MI, or major amputation (Table 4).
Independent predictors of limb-speciﬁc clinical events
included female sex, CLI, chronic kidney disease, multilevel
disease, Trans-Atlantic Inter-Society Consensus for the Man-
agement of Peripheral Arterial Disease C or D lesions, and
previous history of EVT (Table 4).
Sex Disparities According to Initial Presentation
To assess sex differences in clinical outcomes according to
initial presentation, we analyzed data for patients who
presented with CLI or claudication. Interestingly, among
patients with CLI, there were no signiﬁcant differences in
primary outcome between men and women (17.8% versus
15.8%, HR 1.164, 95% CI 0.800-1.694, P=0.426) (Figure 4A).
However, among patients with claudication, women showed
signiﬁcantly higher cumulative incidences of primary outcome
than men (13.2% versus 7.0%, HR 2.088, 95% CI 1.421-3.068,
P<0.001) (Figure 4B). There was a signiﬁcant interaction
(P=0.035) between sex and initial presentation on the primary
Figure 2. In-hospital outcomes and procedural complication rates according to sex. Crude incidences of in-hospital mortality, unexpected
amputation, unexpected reintervention, total procedural complication, bleeding, access site complication, distal embolism, vascular rupture, and
failed or incomplete procedure for men (blue bar) and women (red bar). EVT indicates endovascular treatment.
DOI: 10.1161/JAHA.118.010849 Journal of the American Heart Association 5
Sex Difference of Peripheral Artery Disease Choi et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on May 19, 2019
outcome, which consisted of all-cause death, MI, and major
amputation.
Discussion
In the present study we investigated sex-related disparities in
clinical outcomes for PAD patients undergoing EVT. The major
ﬁndings were as follows: ﬁrst, among EVT-treated PAD
patients, women were on average older than men, with more
complex lesion characteristics and higher rates of comorbidi-
ties. Second, women also had higher rates of procedural
complications, including bleeding, access site complication,
and vascular rupture. Third, cumulative incidences of 2-year
follow-up cardiovascular and limb-speciﬁc adverse events
were signiﬁcantly higher in women than in men, even after
adjustment for baseline differences. Finally, women were
associated with higher risk of adverse events in patients
presented with claudication compared with men, but there
was no signiﬁcant difference of outcomes between the groups
in patients with CLI.
Numerous studies have evaluated sex or gender differ-
ences in cardiovascular disease, and these studies have
consistently shown differences in patterns of presentation,
lesion characteristics, clinical outcomes, and responses to
Table 3. Two-Year Clinical Outcomes Among Patients With Peripheral Artery Disease According to Sex Disparity
Event Rates Unadjusted Adjusted*
Women (n=550) Men (n=2523) HR (95% CI) P Value HR (95% CI) P Value
Death, MI, or major amputation 90 (14.8) 270 (9.8) 1.706 (1.345-2.163) <0.001 1.350 (1.017-1.792) 0.038
All-cause death 54 (9.8) 175 (6.9) 1.474 (1.086-2.000) 0.013 1.203 (0.874-1.656) 0.256
Myocardial infarction 8 (1.8) 18 (1.0) 2.140 (0.931-4.923) 0.073 1.925 (0.790-4.687) 0.149
Major amputation 17 (3.1) 30 (1.2) 2.685 (1.481-4.868) 0.001 1.666 (0.884-3.141) 0.115
Minor amputation 27 (4.9) 78 (3.1) 1.646 (1.062-2.549) 0.026 1.146 (0.730-1.800) 0.554
Total amputation 44 (8.0) 102 (4.0) 2.068 (1.452-2.945) <0.001 1.410 (0.975-2.039) 0.068
Reintervention 57 (10.4) 217 (8.6) 1.280 (0.956-1.713) 0.098 1.279 (0.936-1.748) 0.123
Major adverse limb event† 91 (19.9) 298 (14.5) 1.506 (1.191-1.905) <0.001 1.301 (1.014-1.670) 0.039
Event rate values are n (%). Cumulative incidence of events was presented as Kaplan-Meier estimates. EVT indicates endovascular treatment; HR, hazard ratio; MI, myocardial infarction;
TASC, Trans-Atlantic Inter-Society Consensus.
*Adjusted variables included age, hypertension, diabetes mellitus, chronic kidney disease, current smoking, previous history of amputation, EVT, MI, stroke, bypass surgery, critical limb
ischemia, multilevel disease, at least 1 TASC C or D, and body mass index >30 kg/m2.
†Major adverse limb event (MALE) was deﬁned as major amputation, minor amputation, or reintervention.
Figure 3. Comparison of 2-year clinical outcomes according to sex disparity. Kaplan-Meier curves for comparison of rates of death, MI, or
major amputation (A), and MALE (B) for men (blue lines) and women (red lines). MALE indicates major adverse limb event; MI, myocardial
infarction.
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therapy.20-22 These differences may arise from differences in
biology, termed “sex differences,” or from differences in
sociocultural behavior, termed “gender differences.” Under-
standing sex disparities is important in making proper
diagnoses and delivering optimal treatments for patients with
cardiovascular disease. Therefore, we sought to compare
baseline clinical characteristics, lesion characteristics, proce-
dural outcomes, and follow-up outcomes between men and
women with PAD who underwent EVT. As with previous
studies,12-14 we found that women were older at the time of
presentation and were less likely to be smokers. Furthermore,
our study showed that women had more severe lesion
complexity at the time of revascularization and underwent EVT
more frequently for CLI than did men. Although the etiology of
these differences is unclear, factors such as smaller vessel
size, less physical activity, smaller calf muscle mass, higher
proportion of asymptomatic disease, and more comorbidities
including arthritis or osteoporosis in women may have
contributed to the delay in detection of PAD in women.23-27
Another possibility is that the development of disease in
women may be delayed.
In our cohort, women with PAD tended to have higher rates
of procedural complications such as bleeding, access site
complication, and vascular rupture after EVT. This ﬁnding is
consistent with previous studies.12,14,27 Factors such as
smaller blood vessel diameter, greater incidence of femor-
opopliteal or infrapopliteal disease, and higher rates of
multilevel disease at presentation may contribute to the
higher incidence of procedural complications after EVT in
women. However, the rates of in-hospital mortality and
procedural success rates were not signiﬁcantly different
between women and men, despite a higher incidence of
procedural complications in women. These seemingly contra-
dictory ﬁndings may reﬂect the fact that most procedural
Table 4. Independent Predictors of Clinical Events in Patients
With Peripheral Artery Disease Undergoing EVT
Variable Adjusted HR (95% CI)* P Value
Death, MI or major amputation
Female 1.302 (1.015-1.670) 0.038
Critical limb ischemia 1.469 (1.117-1.933) 0.006
Chronic kidney disease 3.667 (2.824-4.760) <0.001
Previous history of amputation 1.612 (1.113-2.336) 0.011
Previous history of stroke 1.400 (1.050-1.867) 0.022
Previous history of bypass surgery 2.188 (1.262-3.791) 0.005
Age (per 1 increase) 1.040 (1.026-1.055) <0.001
Major adverse limb event
Female 1.301 (1.014-1.670) 0.039
Critical limb ischemia 1.875 (1.491-2.358) <0.001
Chronic kidney disease 1.554 (1.227-1.968) <0.001
Multilevel disease 1.474 (1.196-1.815) <0.001
At least 1 TASC C or D 1.734 (1.308-2.297) <0.001
Previous history of EVT 1.736 (1.304-2.313) <0.001
EVT indicates endovascular treatment; HR, hazard ratio; MI, myocardial infarction; TASC,
Trans-Atlantic Inter-Society Consensus.
*C-index of the Cox regression model of death or amputation and major adverse limb
event were 0.741 (95% CI 0.706-0.776) and 0.713 (95% CI 0.684-0.742), respectively.
Figure 4. Differential rates of primary outcome between men and women according to initial presentation. Kaplan-Meier curves for
comparison of rates of a composite of all-cause death, MI, and major amputation between men (blue line) and women (red line) with CLI (A) or
claudication (B). Interaction P-value for primary outcome and initial presentation (CLI vs claudication) was signiﬁcant (P=0.035). CLI indicates
critical limb ischemia; MI, myocardial infarction.
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complications are treatable and nonfatal. Although numerous
studies have assessed the association of sex and in-hospital
outcomes in PAD patients treated with EVT using large
registry data, most studies have lacked extensive data on
follow-up clinical outcomes and have produced conﬂicting
results. The largest study, based on data from 3 states in
United States, showed that mortality rates for women
undergoing surgical intervention for peripheral artery disease
were substantially higher than those for men, even after
adjustment for comorbidities.27 In addition, the primary or
secondary patency of stents following EVT was poorer in
women than in men.15,28 In contrast, Hussain et al reported
no signiﬁcant sex difference in risk of follow-up all-cause
mortality or major amputation occurring in patients seen by a
vascular surgeon rather than patients undergoing surgical or
endovascular intervention.16 In the present study women had
signiﬁcantly higher rates of 2-year cardiovascular composite
outcomes, which consist of all-cause mortality, myocardial
infarction, and major amputation, as well as limb-speciﬁc
adverse events than men, even after adjustment for con-
founding factors.
Ferranti et al reported no evidence of gender disparity in
reinterventions, major amputation, or survival rates following
EVT for patients with claudication or CLI despite higher rates
of access site complications in women.14 However, McCoach
et al showed women with CLI to be associated with higher
rates of major adverse cardiovascular events despite similar
rates of limb salvage.29 In the present study the results
suggest that sex-related outcomes may differ according to
their clinical presentation. Women with claudication had a
higher incidence of cardiovascular adverse events (Rutherford
classiﬁcation 1, 2, or 3) than men with claudication, but there
was no signiﬁcant difference in outcome between women and
men with CLI (Rutherford classiﬁcation 4, 5, or 6). According
to the current guidelines, revascularization should be per-
formed in CLI patients to minimize tissue loss.2-4 However, in
patients with intermittent claudication, revascularization for a
large-vessel (aortoiliac) short-length lesion was recommended
only for class IA indications. This suggests that the risk-
beneﬁt tradeoff for revascularization should be considered for
patients with intermittent claudication with small-vessel PAD.
Our study showed that women have smaller vessel size, a
higher proportion of femoropopliteal or infrapopliteal disease,
multilevel disease, and a greater incidence of complications
than men. We think that these differences may have
contributed to the signiﬁcantly higher incidence of 2-year
cardiovascular adverse events in female patients with inter-
mittent claudication undergoing EVT. In this regard, physi-
cians should be aware that procedural complications and
prognosis may be poorer when they are treating female
patients with PAD undergoing EVT compared with male
patients, especially when the patient presents with
claudication. Future studies based on larger registry data
sets and longer-term follow-up data would be helpful to
conﬁrm our results.
Study Limitations
The present study had several limitations. First, because of
the retrospective nature of the study, residual or unmeasured
confounding factors could have inﬂuenced the results, even
after multivariable analysis. In particular, choice of treatment
was based on the physician’s discretion. Second, the current
study could be potentially underpowered for evaluating sex
differences because of the relatively small sample size for
women. Nevertheless, our data showed statistically signiﬁcant
differences in outcomes between women and men, and total
population was modest in size. Third, our results cannot be
extrapolated to patients with PAD who did not receive EVT
because our registry did not include PAD patients treated with
surgical intervention or medical therapy alone.
Conclusions
Among a large population of patients with PAD who under-
went EVT, women had higher rates of complex lesions,
procedural complications, death, MI, major amputation, and
limb-speciﬁc adverse events than men. These differences
were particularly pronounced in patients with claudication;
however, no sex disparity was observed in patients with CLI. A
future large observational study is warranted to conﬁrm these
results.
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